1. Home
  2. TTI vs SLDB Comparison

TTI vs SLDB Comparison

Compare TTI & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TTI

Tetra Technologies Inc.

N/A

Current Price

$7.17

Market Cap

1.1B

Sector

Energy

ML Signal

N/A

Logo Solid Biosciences Inc.

SLDB

Solid Biosciences Inc.

N/A

Current Price

$49.45

Market Cap

1.1B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TTI
SLDB
Founded
1981
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
1996
2017

Fundamental Metrics

Financial Performance
Metric
TTI
SLDB
Price
$7.17
$49.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
11
Target Price
$10.40
$16.36
AVG Volume (30 Days)
1.9M
876.6K
Earning Date
04-29-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
34.97
EPS
0.13
N/A
Revenue
N/A
$8,094,000.00
Revenue This Year
$4.70
N/A
Revenue Next Year
$11.35
N/A
P/E Ratio
$52.08
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.44
$3.79
52 Week High
$12.54
$11.45

Technical Indicators

Market Signals
Indicator
TTI
SLDB
Relative Strength Index (RSI) 31.37 56.51
Support Level N/A $5.21
Resistance Level $8.99 $11.45
Average True Range (ATR) 0.37 0.43
MACD -0.12 0.06
Stochastic Oscillator 7.47 67.25

Price Performance

Historical Comparison
TTI
SLDB

About TTI Tetra Technologies Inc.

Tetra Technologies Inc is a diversified oil and gas services company, focused on completion fluids and associated products and services, water management, frac flowback, production well testing, offshore rig cooling, and compression services. It has two reporting segments, namely Completion Fluids & Products and Water & Flowback Services. The Completion Fluids & Products Division manufactures and markets clear brine fluids, additives, and associated products and services. The Water & Flowback Services Segment provides onshore oil and gas operators with comprehensive water management services. The majority of revenue is from the Completion Fluids & Products segment.

About SLDB Solid Biosciences Inc.

Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.

Share on Social Networks: